Roche Holding AG

ROG

CH0012032048

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 09:00:06 16/07/2024 pm IST			5-day change	1st Jan Change
258.9 ^CHF	+0.08%		+5.85%	+5.89%

15/07	ROCHE HOLDINGS AG : Sell rating from Goldman Sachs	ZD
15/07	ROCHE HOLDINGS AG : Gets a Neutral rating from Deutsche Bank	ZD

ROCHE HOLDINGS AG : UBS remains Neutral

January 20, 2023 at 05:25 pm IST

Analyst Michael Leuchten from UBS research gives the stock a Neutral rating. The target price remains unchanged at CHF 315.

Latest news about Roche Holding AG

ROCHE HOLDINGS AG : Sell rating from Goldman Sachs	15/07	ZD
ROCHE HOLDINGS AG : Gets a Neutral rating from Deutsche Bank	15/07	ZD
ROCHE HOLDINGS AG : JP Morgan maintains a Sell rating	11/07	ZD
DexCom, Inc. : A Must-Have Tool for Diabetes Care	10/07
Markets Powered by Alternating Current	10/07
ROCHE HOLDINGS AG : Deutsche Bank gives a Neutral rating	10/07	ZD
ROCHE HOLDINGS AG : UBS gives a Neutral rating	10/07	ZD
SIX to Cap SLI Index Weight of Nestle, Novartis Roche, UBS	10/07	MT
Swiss Market Index Closes in the Red; Roche Rises	09/07	MT
Mixed feelings	09/07
ROCHE HOLDINGS AG : UBS remains Neutral	09/07	ZD
Roche: CE marking in diabetes monitoring	09/07	CF
Roche Secures CE Mark for AI-powered Continuous Glucose Monitoring Device	09/07	MT
Roche Receives CE Mark for Its AI-Enabled Continuous Glucose Monitoring Solution Offering Critical Predictions to People Living with Diabetes	09/07	CI
Roche Secures FDA Nod to Relaunch Susvimo in US After Recall	09/07	MT
Roche launches recalled eye implant in US	08/07	RE
Roche Gets FDA Approval to Reintroduce Eye Implant Susvimo to the U.S.	08/07	DJ
Roche: reintroduces Susvimo, FDA validates updates	08/07	CF
Roche reintroduces recalled eye implant in US	08/07	RE
Roche to Reintroduce Susvimo in the US for People with Neovascular Age-Related Macular Degeneration	08/07	CI
Global markets live: Apple, Samsung, Shell, Tesla, KKR...	05/07
Trending : Roche to Halt Lung-Cancer Trials After Treatment Misses Goals	05/07	DJ
ROCHE HOLDINGS AG : Deutsche Bank gives a Neutral rating	05/07	ZD
Roche: new approval for Vabysmo in the United States	05/07	CF
ROCHE HOLDINGS AG : JP Morgan reiterates its Sell rating	05/07	ZD

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Sector

Pharmaceuticals

Calendar

23/07/2024 - American Society of Retina Specialists Meeting

Related indices

SMI , STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

ROCHE HOLDING : In line quarterly results won’t cut it for Roche

April 24, 2024 at 09:20 pm IST

Obesity: Roche joins the battle

December 04, 2023 at 09:18 pm IST

More Strategies

Ratings for Roche Holding AG

Trading Rating

Investor Rating

ESG Refinitiv

A+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

258.7 CHF

Average target price

274 CHF

Spread / Average Target

+5.91%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ROCHE HOLDING AG	+5.89%	23TCr
ELI LILLY AND COMPANY	+62.02%	86TCr
NOVO NORDISK A/S	+38.95%	63TCr
JOHNSON & JOHNSON	-4.17%	36TCr
MERCK & CO., INC.	+15.57%	32TCr
ABBVIE INC.	+9.22%	30TCr
NOVARTIS AG	+16.53%	23TCr
AMGEN INC.	+16.13%	18TCr
PFIZER, INC.	+2.31%	16TCr
SANOFI	+2.41%	13TCr

Other Pharmaceuticals

Roche Holding AG

Equities

ROG

CH0012032048

Pharmaceuticals

ROCHE HOLDINGS AG : UBS remains Neutral

Latest news about Roche Holding AG

Chart Roche Holding AG

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Roche Holding AG

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals